SGRY Strangle Strategy
SGRY (Surgery Partners, Inc.), in the Healthcare sector, (Medical - Care Facilities industry), listed on NASDAQ.
Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2021, it owned or operated a portfolio of 126 surgical facilities, including 108 ambulatory surgical centers and 18 surgical hospitals in 31 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.
SGRY (Surgery Partners, Inc.) trades in the Healthcare sector, specifically Medical - Care Facilities, with a market capitalization of approximately $1.87B, a beta of 1.99 versus the broader market, a 52-week range of 11.41-24.18, average daily share volume of 1.6M, a public-listing history dating back to 2015, approximately 15K full-time employees. These structural characteristics shape how SGRY stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.99 indicates SGRY has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on SGRY?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current SGRY snapshot
As of May 15, 2026, spot at $13.89, ATM IV 53.10%, IV rank 30.10%, expected move 15.22%. The strangle on SGRY below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on SGRY specifically: SGRY IV at 53.10% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 15.22% (roughly $2.11 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SGRY expiries trade a higher absolute premium for lower per-day decay. Position sizing on SGRY should anchor to the underlying notional of $13.89 per share and to the trader's directional view on SGRY stock.
SGRY strangle setup
The SGRY strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SGRY near $13.89, the first option leg uses a $14.58 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SGRY chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SGRY shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $14.58 | N/A |
| Buy 1 | Put | $13.20 | N/A |
SGRY strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
SGRY strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on SGRY. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on SGRY
Strangles on SGRY are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SGRY chain.
SGRY thesis for this strangle
The market-implied 1-standard-deviation range for SGRY extends from approximately $11.78 on the downside to $16.00 on the upside. A SGRY long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current SGRY IV rank near 30.10% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on SGRY should anchor more to the directional view and the expected-move geometry. As a Healthcare name, SGRY options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SGRY-specific events.
SGRY strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SGRY positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SGRY alongside the broader basket even when SGRY-specific fundamentals are unchanged. Always rebuild the position from current SGRY chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on SGRY?
- A strangle on SGRY is the strangle strategy applied to SGRY (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With SGRY stock trading near $13.89, the strikes shown on this page are snapped to the nearest listed SGRY chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are SGRY strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the SGRY strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 53.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a SGRY strangle?
- The breakeven for the SGRY strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SGRY market-implied 1-standard-deviation expected move is approximately 15.22%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on SGRY?
- Strangles on SGRY are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SGRY chain.
- How does current SGRY implied volatility affect this strangle?
- SGRY ATM IV is at 53.10% with IV rank near 30.10%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.